Navigation Links
Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
Date:8/25/2008

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2008 Results
2. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
3. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
6. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
7. Neurocrine Announces Work Force Restructuring
8. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
9. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
10. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... NATICK, Mass. and SAN FRANCISCO, Nov. 8, 2011 ... ) reports positive long-term data from the PERSEUS ... effectiveness outcomes for the ION™ (TAXUS Element) Paclitaxel-Eluting ...  Results were presented today by PERSEUS clinical program ...
... SQUARE, Pa., Nov. 8, 2011 Kibow Biotech, Inc. ... of Renal Week, it is changing the brand name ... Kibow® Biotics, this patented and clinically tested probiotic formulation ... there is growing recognition of the scientific and health ...
... Valkee ( http://valkee.com ), the inventor ... from the University of Oulu present two clinical trials ... Anxiety Disorders in Budapest on November 9 th -11 ... the peer-reviewed conference supplement of the International Journal of ...
Cached Biology Technology:Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 2Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 3Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 4Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program 5Kibow Changes Name of Flagship Kidney Function Support Product to 'RENADYL™' 2Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu 2Bright Light into the Ear Canal Treats Seasonal Depression Effectively in Two Clinical Trials Presented by Valkee and University of Oulu 3
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Cambridge, Mass., and Worcester, Mass., March 1, 2012 ... RNAi therapeutics company, and the University of Massachusetts ... Patent Office (EPO) has upheld the Tuschl I ... held in Munich, Germany. The requested claims of ...
... Italian and Swiss researchers confirm that induced hyperammonaemia significantly ... available in the March issue of Hepatology , ... American Association for the Study of Liver Diseases, show ... of cirrhotic patients to produce restorative sleep. ...
... with implants. Often following the procedure, they are unable to ... has become fixated in the bone. Now, for the first ... allows titanium screws to adhere to the bone better and ... results are good. The study, led by Per Aspenberg, ...
Cached Biology News:Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings 2Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings 3Cirrhotic patients experience increased daytime sleepiness from higher ammonia levels 2New method for stronger dental implants 2
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' overhang ... polymerase which exhibits very high activity in ... To ensure the quality of the enzyme, ...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: